阿司匹林与口服抗凝药在关节置换术后静脉血栓栓塞预防中同样有效且安全:随机临床试验的系统综述与Meta分析
该系统综述与Meta分析纳入11项随机对照试验共4717例接受关节置换术的成人,比较阿司匹林与口服抗凝药预防静脉血栓栓塞的效果与安全性。结果显示阿司匹林组静脉血栓栓塞相对风险为1.11(95%CI 0.93-1.32),深静脉血栓和肺栓塞结果相似,出血、伤口并发症和死亡率无显著差异。基于高质量证据,阿司匹林与口服抗凝药同样有效且安全。
要点
- 阿司匹林与口服抗凝药相比,关节置换术后静脉血栓栓塞风险无显著差异(RR 1.11,95%CI 0.93-1.32)。
- 深静脉血栓(RR 1.12,95%CI 0.90-1.40)和肺栓塞(RR 1.18,95%CI 0.51-2.71)结果相似。
- 出血、伤口并发症和死亡率在两组间无显著差异。
核心结论
- 基于随机对照试验的高质量证据,阿司匹林在关节置换术后预防静脉血栓栓塞(包括深静脉血栓和肺栓塞)方面与口服抗凝药同样有效且安全,不增加并发症。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Web of Science和Cochrane Library截至2024年5月14日的随机对照试验,纳入11项随机对照试验共4717例接受关节置换术的成人(55.1%为女性),来自多个洲,采用随机效应模型估计效应。
主要发现
- 阿司匹林组与口服抗凝药组相比,静脉血栓栓塞的相对风险为1.11(95%CI 0.93-1.32)。
- 深静脉血栓的相对风险为1.12(95%CI 0.90-1.40),肺栓塞的相对风险为1.18(95%CI 0.51-2.71)。
- 出血、伤口并发症和死亡率在阿司匹林组与口服抗凝药组之间无显著差异。
- 亚组分析考虑研究地区、关节手术类型、静脉血栓栓塞检测类型、发表年份、机械性静脉血栓栓塞预防的使用、阿司匹林剂量、口服抗凝药对照类型、研究质量和资金等因素,均未发现阿司匹林与口服抗凝药之间静脉血栓栓塞发生率的显著差异。
- 静脉血栓栓塞和深静脉血栓结局的总体证据质量高。
关键数值与推荐
- 静脉血栓栓塞相对风险:阿司匹林组 vs 口服抗凝药组为1.11(95%CI 0.93-1.32)。
- 深静脉血栓相对风险:阿司匹林组 vs 口服抗凝药组为1.12(95%CI 0.90-1.40)。
- 肺栓塞相对风险:阿司匹林组 vs 口服抗凝药组为1.18(95%CI 0.51-2.71)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Joint arthroplasty effectively treats osteoarthritis, providing pain relief and improving function, but postoperative venous thromboembolism (VTE) remains a common complication. This study therefore assessed the effectiveness and safety of aspirin compared with oral anticoagulants (OACs) for VTE prophylaxis after joint arthroplasty. METHODS: A systematic review and meta-analysis was performed by searching PubMed, Embase, the Web of Science, and the Cochrane Library for randomized controlled trials (RCTs) up to May 14, 2024, that compared the effect of aspirin versus OACs on VTE prophylaxis in adults undergoing joint arthroplasty. Data extraction followed the PRISMA guidelines. Two independent researchers conducted the literature searches and data extraction. A random-effects model was used to estimate effects. The primary outcome was the incidence of VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE); secondary outcomes included bleeding, wound complications, and mortality. RESULTS: The meta-analysis included 11 RCTs with a total of 4,717 participants (55.1% female) from several continents. The relative risk (RR) of VTE following joint arthroplasty was 1.11 (95% confidence interval [CI], 0.93 to 1.32) for aspirin compared with OACs. Similar results were observed for DVT (RR, 1.12; 95% CI, 0.90 to 1.40) and PE (RR, 1.18; 95% CI, 0.51 to 2.71). There were no significant differences in the risks of bleeding, wound complications, or mortality between patients receiving aspirin and those receiving OACs. Subgroup analyses considering factors such as study region, type of joint surgery, type of VTE detection, year of publication, use of mechanical VTE prophylaxis, aspirin dose, type of OAC comparator, study quality, and funding also found no significant differences in VTE incidence between aspirin and OACs. The overall quality of evidence for VTE and DVT outcomes was high. CONCLUSIONS: Based on high-quality evidence from RCTs, aspirin is as effective and safe as OACs in preventing VTE, including DVT and PE, after joint arthroplasty, without increasing complications. LEVEL OF EVIDENCE: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
引用
- Hong Z, Su Y, Zhang L, et al. Aspirin Is as Effective and Safe as Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Joint Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Bone Joint Surg Am. 2025. PMID: 39836735. doi:10.2106/JBJS.24.00946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。